MENU
WORLDALLERGY.ORG
Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Instagram: World Allergy Organization
Back to Top

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial